银杏酮酯分散片治疗缺血性心脑血管疾病临床应用专家共识  

Expert consensus on clinical application of GBE50 Dispersible Tablets for ischemic cardiovascular and cerebrovascular diseases

作　　者：杨文明[1] 汪瀚[1] 孙塑伦[2] 张允岭 陈晓虎[4] 卢健棋[5] 吴波水[6] 孙建宁[7] 陈薇[7] 唐露露 代表编制组 YANG Wen-ming;WANG Han;SUN Su-lun;ZHANG Yun-ling;CHEN Xiao-hu;LU Jian-qi;WU Bo-shui;SUN Jian-ning;CHEN Wei;TANG Lu-lu;represented the editorial team(the First Hospital Affiliated to Anhui University of Chinese Medicine,Hefei 230031,China;Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Jiangsu Province Hospital of Chinese Medicine,Nanjing 210004,China;the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530022,China;Huashan Hospital Affiliated to Fudan University,Shanghai 200040,China;Beijing University of Chinese Medicine,Beijing 100105,China;不详)

机构地区：[1]安徽中医药大学第一附属医院,安徽合肥230031 [2]北京中医药大学东直门医院,北京100700 [3]中国中医科学院西苑医院,北京100091 [4]江苏省中医院,江苏南京210004 [5]广西中医药大学第一附属医院,广西南宁530022 [6]复旦大学附属华山医院,上海200040 [7]北京中医药大学,北京100105 [8]不详

出　　处：《中国中药杂志》2022年第2期301-305,共5页China Journal of Chinese Materia Medica

基　　金：中华中医药学会标准化项目(GS/CACM279-2020)。

摘　　要：银杏酮酯分散片是一种新型的银杏叶提取物标准化制剂,广泛用于治疗缺血性心脑血管疾病,但在临床应用中仍存在许多问题,合理、安全地使用银杏酮酯分散片,是影响患者用药安全、临床预后的关键。该共识由国内心脑血管领域的中西医临床专家共同制定,遵循中华中医药学会发布的《中成药临床应用专家共识的制订流程》,在充分调研临床需求的基础上确定临床问题,依据PICO化的临床问题检索文献,采用国际公认的证据分级推荐标准--GRADE系统开展证据评价、分级和推荐,并采用名义组法形成专家共识。如果证据充分则形成"推荐意见",采用GRADE网格计票规则;如果证据不充分,则形成"共识建议",采用多数计票规则。该共识推荐了银杏酮酯分散片临床应用中的适应症、用法用量、特殊人群用药、安全性等,旨在提高临床疗效,促进规范合理用药,减少用药风险。该共识仍需在未来根据实际应用中针对新出现的临床问题及循证证据的更新予以修订。Ginkgo biloba Extract(GBE50)Dispersible Tablets is a new standardized prescription,which is widely used in the treatment of ischemic cardiovascular and cerebrovascular diseases.However,there are still many problems in its clinical application.Rational and safe use of GBE50 Dispersible Tablets is pivotal to the medication safety and clinical prognosis of patients.This consensus has been jointly formulated by clinical experts of traditional Chinese medicine and western medicine in cardiovascular and cerebrovascular diseases and followed the Manual for the Clinical Experts Consensus of Chinese Patent Medicine published by the China Association of Chinese Medicine.The present study identified clinical problems based on clinical investigation,searched the research papers according to PICO clinical problems,carried out evidence evaluation,classification,and recommendation by GRADE system,and reached the expert consensus with nominal group technique.The consensus combines evidence with expert experience.Sufficient evidence of clinical problems corresponds to"recommendations",while insufficient evidence to"suggestions".Safety issues of GBE50 Dispersible Tablets,such as indications,usage and dosage,and medication for special populations,are defined to improve clinical efficacy,promote rational medication,and reduce drug risks.This consensus needs to be revised based on emerging clinical issues and evidencebased updates in practical applications in the future.

关 键 词：银杏酮酯分散片 专家共识 心脑血管疾病 推荐意见 GRADE 

分 类 号：R277.7[医药卫生—中医学] R259